Chardan Capital reiterated their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX) in a research report released on Wednesday, TipRanks reports. They currently have a $15.00 price target on the biotechnology company’s stock.
Several other research analysts have also recently issued reports on VKTX. BidaskClub cut Viking Therapeutics from a hold rating to a sell rating in a research report on Wednesday, July 15th. Stifel Nicolaus reiterated a buy rating and issued a $14.00 price objective on shares of Viking Therapeutics in a research report on Wednesday. BMO Capital Markets assumed coverage on Viking Therapeutics in a research report on Thursday, June 4th. They issued an outperform rating and a $14.00 price objective for the company. William Blair reiterated a buy rating on shares of Viking Therapeutics in a research report on Friday, April 3rd. Finally, BTIG Research assumed coverage on Viking Therapeutics in a research report on Friday, May 1st. They issued a buy rating and a $9.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Buy and an average target price of $14.78.
Viking Therapeutics stock opened at $7.02 on Wednesday. Viking Therapeutics has a 12 month low of $3.26 and a 12 month high of $8.87. The business has a 50 day simple moving average of $7.11 and a 200-day simple moving average of $6.41.
In other Viking Therapeutics news, Director Matthew W. Foehr sold 13,000 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $7.35, for a total value of $95,550.00. Following the sale, the director now owns 26,250 shares of the company’s stock, valued at $192,937.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.70% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of VKTX. Royal Bank of Canada boosted its stake in shares of Viking Therapeutics by 3.7% during the first quarter. Royal Bank of Canada now owns 47,655 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 1,693 shares during the last quarter. Brinker Capital Inc. boosted its stake in shares of Viking Therapeutics by 6.1% during the second quarter. Brinker Capital Inc. now owns 31,712 shares of the biotechnology company’s stock valued at $229,000 after acquiring an additional 1,811 shares during the last quarter. Creative Planning boosted its stake in shares of Viking Therapeutics by 7.6% during the first quarter. Creative Planning now owns 42,573 shares of the biotechnology company’s stock valued at $199,000 after acquiring an additional 3,000 shares during the last quarter. Verus Capital Partners LLC acquired a new stake in shares of Viking Therapeutics during the fourth quarter valued at $26,000. Finally, Great West Life Assurance Co. Can acquired a new stake in shares of Viking Therapeutics during the fourth quarter valued at $30,000. 54.21% of the stock is currently owned by institutional investors.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis.
Featured Article: What is the Beige Book?
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.